Servier has entered exclusive negotiations with BC Partners for the potential sale of Biogaran, aiming to focus on innovative therapies while enhancing Biogaran's growth in the French generic medicines market.

Target Information

Biogaran is a leading player in the generic medicine sector in France, having established itself as the top provider of reimbursable generic medications for the past three years. With over 250 employees and a net statutory turnover of €1.122 million for 2023-2024, Biogaran boasts an impressive portfolio that includes 1,078 references and sells 356 million boxes of medication annually. The company operates entirely through subcontracting, with 89% of its production taking place in Europe, including almost 50% in France, ensuring its role in the local healthcare system.

Industry Overview

The generic pharmaceuticals industry in France plays a crucial role in the healthcare landscape, providing accessibility to affordable medications. Over the past few years, there has been a noticeable increase in demand for generics, driven by a growing emphasis on cost containment in healthcare. As the French government continues to encourage the substitution of branded medications with generics, the market is poised for further growth.

Additionally, the introduction of biosimilars has opened new avenues within the generics market. These biologic medications, which are highly similar to already approved reference products, are gaining trac